November Monthly Price Drop: ₹80,000 all-inclusive until 16 November, 11:59 PM IST. 52% off.|Foresight ₹1,40,000 ₹67,797 + 18% GST|12 months of accessGet Foresight
All board jobs
India ID ExchangeLong Term — seat in ~6 months Upcoming Board Seat Foresight Priority Period · until 6 Dec Confidential Role · Foresight Private-company listingPE/VC-Backed Company Governance

Board Advisor — PE-Backed Women’s Health Platform

Confidential private company Bengaluru· Healthcare & Life Sciences
Clinical QualityRiskInvestment

How this seat is filled

When can I apply?

Posted 13 August 2026. Nothing here is behind a payment — a membership changes when your application is read, never whether you can send it.

  1. 1

    Anyone can apply, from day one

    Register free, sit the board-readiness assessment, upload your board CV and apply. No membership is needed to apply to this seat or any other.

  2. 2

    Applications go to the board every 15 days

    The next round for this seat is 26 November 2026.

  3. 3

    Foresight members are read until 7 December 2026

    Those rounds are drawn from Foresight members. If the board appoints from them, the seat closes on appointment.

  4. 4

    Everyone else is read from 7 December 2026

    If the board has not appointed by then, every other application is read in the following round. Your application sits in a queue until that date — the panel beside the brief shows it to the second.

Foresight

Be read in the first round, not after it

Foresight members on this seat are read on 26 November 2026. Without it your application waits until 7 December 2026 — and if the board appoints in between, it is never read at all.

Get Foresight

Board Advisor — PE-Backed Healthcare Startup

Women’s Reproductive Health & Fertility Platform | Clinical Outcomes, Ethical Growth and Buy-and-Build Scale

Company: Confidential, private-equity-backed healthcare platform
Board base: Bengaluru, with periodic clinic and laboratory visits in Hyderabad, Pune and selected Tier-II cities
Position: Board Advisor — non-statutory, non-fiduciary advisory appointment
Reports to: Chair of the Board, with structured access to the founders, sponsor representatives and Chief Executive Officer
Expected commitment: 22–28 days annually, including Board advisory sessions, clinical-quality reviews, acquisition assessments, operating visits and an annual strategy off-site
Appointment term: Initial 24 months, renewable by mutual agreement

IICA membership is not required. This is a Board Advisor appointment and not an Independent Director or statutory Board position. Membership of the IICA Independent Directors Databank, a DIN and the IICA proficiency assessment are therefore not eligibility conditions for this role.

The company

The company is developing an integrated women’s reproductive-health platform anchored in fertility assessment, assisted reproductive treatment, embryology, reproductive genetics, fertility preservation and related women’s health services. It operates a growing network of full-service centres, satellite consultation clinics and centralised or hub-linked laboratories.

The platform has secured institutional private-equity backing to professionalise a founder-led clinical business, expand into underserved cities, acquire high-quality regional centres and create a trusted national care model. Its next phase will involve a combination of brownfield capacity, greenfield clinics, clinician partnerships, selective acquisitions and technology-enabled patient coordination.

The opportunity is substantial, but the category is unusually sensitive. Success rates can be difficult for patients to interpret. Treatment is expensive, emotionally demanding and clinically uncertain. Commercial incentives can influence diagnostics, treatment cycles, add-on procedures, donor programmes and marketing claims. The quality of an embryology laboratory may depend on a small number of specialists, tightly controlled environmental conditions and disciplined processes that are not visible in ordinary financial reporting.

The company wants to build a healthcare institution whose growth is earned through reproducible clinical quality, ethical patient treatment and disciplined capital deployment—not through aggressive conversion, opaque outcome claims or serial acquisitions held together only by a common brand.

Market hint: A sponsor-backed platform combining founder-led fertility centres, embryology laboratories, reproductive genetics and an acquisition-led Tier-I/Tier-II expansion plan may resemble a small group of emerging Indian women’s health networks. No founder, investor, clinic brand, doctor, transaction or city-level asset is identified.

The advisory opportunity

The Board seeks a senior healthcare leader who can help the company become institutionally scalable without stripping away clinical judgement, patient trust or the local strengths of acquired centres. The advisor will bring an independent external perspective across clinical governance, network design, acquisitions, clinician alignment, patient economics, ethical marketing, technology, organisational capability and exit readiness.

This is a working advisory role. The successful candidate will be expected to examine clinical and operating evidence, visit care settings, challenge investment assumptions and help the Board resolve difficult trade-offs. The advisor must be comfortable telling founders, clinicians, management and the private-equity sponsor when growth ambitions exceed the maturity of laboratories, people, systems or patient safeguards.

The role carries no statutory director authority. The advisor will not vote at Board meetings, approve reserved matters, sign regulatory filings, determine individual treatment, supervise clinicians, issue medical instructions or act as management. All formal decisions remain with the Board and authorised executives. Advice must be clearly identified as advisory and recorded through the company’s agreed governance process.

Core advisory mandate

1. Define the institution the platform intends to become

Help the Board translate a broad growth thesis into a clear strategic identity. Determine whether the platform’s distinctive promise is superior clinical outcomes, safe and ethical access, complex-case capability, affordability, geographic convenience, continuity across women’s health or a defensible combination of these elements.

Challenge strategies that attempt to be simultaneously premium, mass-market, highly personalised and operationally standardised without making the necessary choices. Advise the Board on which patient segments, clinical services, cities and channels the company should serve—and which opportunities should be declined because they weaken quality, trust or returns.

2. Establish a credible clinical-governance architecture

Advise on the creation of a group clinical council with clearly defined authority over protocols, credentials, laboratory quality, outcome definitions, adverse events and ethical standards. The council should support clinical judgement while identifying variation that cannot be explained by patient mix or accepted practice.

Recommend escalation thresholds for ovarian hyperstimulation, procedural complications, infection, anaesthesia events, medication errors, sample or identity incidents, embryo-storage deviations, genetic-testing errors, unexpected hospital transfer and serious patient complaints. The objective is not zero reporting; it is early reporting, honest learning and verified prevention of recurrence.

Help the Board distinguish clinical quality assurance from professional protection. Eminence, founder status or revenue contribution must not prevent review of unexplained outcome variation, repeated patient concerns or departure from approved practice.

3. Make treatment outcomes comparable and honest

Advise on an outcome framework that separates consultation, treatment start, oocyte retrieval, fertilisation, blastocyst development, transfer, biochemical pregnancy, clinical pregnancy, ongoing pregnancy, live birth and healthy singleton birth. Measures should be segmented by patient age, diagnosis, treatment type, use of donor material, embryo stage, fresh or frozen cycle and other material clinical factors.

Challenge selective denominators, exclusion of difficult cases, mixing of cumulative and per-transfer outcomes, and advertising that presents pregnancy as a guaranteed result. Recommend independent validation of high-stakes outcome claims before publication.

Encourage the Board to track time to outcome, treatment discontinuation, multiple pregnancy, cycle cancellation, patient-reported experience and financial burden alongside headline success rates. The most marketable number is not necessarily the measure that best protects patients or builds durable trust.

4. Protect embryology and laboratory integrity

Support a network-wide laboratory-governance system covering chain of identity, witnessing, specimen labelling, access, incubator conditions, gas quality, temperature, air quality, cryostorage, alarms, power, preventive maintenance, calibration, consumables, media, documentation and emergency response.

Advise on staffing ratios, competence assessment, second-person checks, electronic witnessing and succession for laboratory leaders. Recommend minimum conditions for launching or acquiring a laboratory, including case volume, senior supervision, backup systems, equipment redundancy and validated transport where samples or reproductive material move between sites.

Require the company to simulate high-consequence events: power interruption, incubator failure, alarm non-response, tank depletion, misidentification, cyber outage and evacuation. A written protocol is insufficient unless teams can execute it under time pressure.

5. Govern patient selection and treatment appropriateness

Help the Board examine how diagnosis, prognosis, patient preference, treatment intensity and commercial incentives interact. Recommend peer review of repeated cycles, unusually high procedure use, routine add-ons, premature escalation and treatment where the chance of success is remote.

Advise on standards for communicating prognosis, alternatives, cumulative cost, likely number of cycles, risks and stopping points. Patients must receive realistic information without having hope manipulated as a sales tool.

Support a process for complex or ethically sensitive cases that brings together clinical, legal and psychosocial judgement. The advisor will not decide individual cases but should ensure the institution has appropriate expertise, documentation and escalation.

6. Set ethical boundaries for add-ons and innovation

Review the company’s governance of adjunct tests, procedures and technologies whose clinical benefit may vary by patient or remain uncertain. Recommend an evidence classification that distinguishes established care, selectively useful intervention, emerging practice and experimental offering.

Advise that pricing, consent and marketing disclose the quality of evidence, additional burden and uncertainty. Clinicians should retain the ability to use judgement, but the organisation must identify unexplained utilisation patterns and prevent revenue targets from driving routine use.

Assess new reproductive technologies, AI-supported embryo assessment, genetic tools, remote monitoring and automated patient guidance for clinical validity, data quality, bias, explainability, human oversight and patient consent before scale deployment.

7. Strengthen consent, counselling and patient dignity

Advise on consent as an ongoing process rather than a form signed before treatment. Patients and partners should understand procedures, alternatives, material risks, embryo disposition, storage, genetic information, donor arrangements, data use, future contact, withdrawal and financial obligations.

Recommend minimum counselling standards for treatment failure, pregnancy loss, donor programmes, fertility preservation, genetic findings, complex family circumstances and discontinuation of care. Counsellors should have professional independence and must not operate primarily as conversion or retention staff.

Help the Board build patient safeguards against coercion, discrimination, stigma, privacy invasion and exploitative financing. Patient communication should remain respectful across marital status, age, diagnosis, economic background and treatment outcome, subject to applicable eligibility requirements.

8. Align clinicians without commercialising judgement

Review employment, partnership, revenue-share, minimum-guarantee, referral and retention structures for clinicians. Advise the Board on incentives that reward quality, patient experience, documentation, teamwork and responsible resource use—not procedure count or cycle conversion alone.

Help create transparent rules for clinician equity, earn-outs, brand use, outside practice, referral, succession and intellectual contribution. Acquired founders should understand when they act as clinicians, managers, shareholders or sellers; conflicts between these roles must be surfaced rather than personalised.

Support the development of clinical leadership beyond a small group of star doctors. The platform’s value should not disappear if one clinician leaves, reduces practice or disagrees with the sponsor.

9. Build a disciplined clinic-network model

Advise on the appropriate mix of full-service centres, satellite clinics, consultation points and central capabilities. Each location should have a defined clinical scope, referral route, emergency plan, staffing model, equipment standard and economic purpose.

Recommend launch gates based on catchment need, referral depth, clinician availability, laboratory support, local competition, patient affordability, licence readiness and time to cash break-even. A signed lease and hired doctor do not establish a viable clinical centre.

Challenge city expansion driven primarily by investor milestones or competitor presence. The Board should compare greenfield entry, clinician partnership and acquisition using quality-adjusted returns and execution capacity.

10. Advise on acquisition selection and diligence

Help the sponsor and Board evaluate targets through four lenses: clinical integrity, economic quality, integration feasibility and leadership character. Diligence should examine source data behind outcomes, patient complaints, laboratory controls, licences, adverse events, clinician contracts, payer and referral patterns, related parties, cash practices, tax exposure and equipment condition.

Recommend explicit deal-breakers, remediation conditions, escrow or holdback mechanisms and post-close clinical gates. Attractive EBITDA should not cure unreliable outcomes, weak identity controls, undisclosed incidents or dependence on ethically questionable patient acquisition.

Advise on the difference between transferable enterprise value and a founder’s personal practice. Forecasts must account for patient loyalty, referral leakage, clinician time, local brand dependence and the possibility that earn-out incentives distort care.

11. Shape post-acquisition integration

Recommend a 100-day and 12-month integration sequence that protects patient continuity while establishing non-negotiable standards. Identity, cryostorage, medication, consent, emergency, privacy and financial controls require early harmonisation; clinical protocols and local operating practices may need evidence-based transition rather than immediate uniformity.

Advise the Board on which functions should be centralised—procurement, finance, technology, analytics, marketing and selected quality systems—and which require strong local accountability. Centralisation must deliver control or capability, not merely shift cost to a corporate office.

Track integration through clinical, people, patient and cash indicators. Rebranding, reporting-line changes and consolidated financials are not proof that an acquired centre has been integrated.

12. Improve patient acquisition and marketing conduct

Examine lead sources, agency relationships, doctor referrals, digital campaigns, call-centre scripts, influencer activity, financing partnerships and channel incentives. Advise the Board on practices that may create misleading urgency, guaranteed-outcome impressions, selective success statistics or inappropriate inducements.

Recommend governance over marketing claims, testimonials, before-and-after narratives, price packages and free assessments. Clinical leaders and compliance personnel should approve material clinical claims before publication.

Help management shift from lead-volume optimisation toward trusted patient acquisition measured through qualified consultations, informed decisions, treatment suitability, patient experience, complaint levels and lifetime trust.

13. Make unit economics clinically meaningful

Advise on centre- and cohort-level economics after clinician cost, laboratory staffing, medicines, consumables, occupancy, marketing, counselling, central allocation, refunds, financing cost and adverse-event burden. Management should distinguish cash collections, booked packages, treatment starts, completed cycles and recognised revenue.

Challenge revenue growth created by aggressive advance collection, non-refundable terms, repeat procedures or acquired volume without comparable clinical and cash performance. Recommend reporting of cancellation, refund, package expiry, unutilised balance and bad debt.

Help the Board assess affordability initiatives and financing partnerships. Access can expand demand, but credit must not encourage patients to pursue low-probability treatment without understanding repayment obligations.

14. Govern procurement and conflicts of interest

Advise on tendering, clinical evaluation, formulary decisions and vendor concentration for medicines, hormones, consumables, culture media, genetic tests, equipment and outsourced diagnostics. Quality and continuity should be balanced with price using transparent, auditable criteria.

Recommend disclosure and recusal standards for clinicians who receive speaker fees, research support, travel, consulting income or other benefits from suppliers. Group rebates and sponsorships must not influence individual patient treatment without clinical justification.

Support resilience planning for critical imported consumables, equipment service and cold-chain requirements. Alternatives must be technically qualified before supply disruption occurs.

15. Protect reproductive, genetic and family data

Advise on governance for medical history, fertility status, sexual and reproductive information, genetic results, donor data, images, financial records and stored reproductive-material records. Access should follow role and purpose; sensitive information must not become broadly visible because it is commercially useful.

Recommend clear rules for consent, retention, research, model training, cross-entity sharing, patient access, correction, deletion where permissible and breach notification. Acquired databases and historical consent should be reviewed before being combined or repurposed.

Require cyber-recovery planning that protects both information and clinical continuity. The company must be able to identify patients, maintain treatment schedules, preserve laboratory traceability and communicate safely during a system outage.

16. Develop a scalable leadership and culture model

Advise the Chief Executive Officer and Board on the organisation required for the next three years: clinical leadership, laboratory leadership, nursing, quality, operations, finance, technology, people, legal and patient experience.

Help define decision rights between founders, sponsor representatives, corporate executives and centre leaders. Private-equity ownership should improve accountability without creating a parallel operating hierarchy or requiring management to satisfy multiple informal principals.

Recommend succession and retention plans for roles where departure could threaten patient continuity, laboratory operations or acquisition value. Culture indicators should include speaking-up, incident reporting, clinician collaboration, patient complaints, attrition and whether bad news travels upward quickly.

17. Guide value creation and exit readiness

Help the Board connect its exit ambition with the institution it must build. A strategic buyer, secondary sponsor or public market will examine outcome reliability, clinical governance, promoter dependence, centre cohorts, compliance, data integrity, clinician contracts and repeatable integration—not only revenue and EBITDA.

Advise on a value-creation scorecard that balances same-centre growth, mature-centre cash generation, clinical outcomes, patient trust, integration, leadership depth and return on invested capital.

Challenge financial engineering, short-term cost reduction or marketing intensity that improves near-term earnings while weakening care or future diligence. Exit preparation should be the consequence of institutional quality, not a cosmetic project begun near the transaction.

Questions expected to reach the advisor

  • Should the company acquire a profitable regional centre whose reported outcomes are strong but whose underlying definitions and laboratory records are inconsistent?
  • Should a high-profile clinician receive a revenue-linked retention package when the proposed structure may influence treatment intensity?
  • Can the group publish a national success rate when centres have different patient mixes, practices and data maturity?
  • Should the platform open a full laboratory in a Tier-II market or use a satellite model until volume, staffing and emergency capability mature?
  • How should the Board respond when a commercially valuable treatment add-on has weak evidence but strong patient demand?
  • Which integration controls must be imposed immediately after an acquisition, and which clinical practices require a measured transition?
  • Should expansion continue when network EBITDA is improving but senior embryologist capacity, quality leadership and incident reporting are not keeping pace?
  • What evidence should be required before investing in AI-supported embryo assessment or automated patient recommendations?
  • When should an acquired founder’s operational authority be reduced because institutional processes are not being accepted?
  • How should the platform balance patient affordability with package design, financing and sustainable clinical economics?

Candidate profile

Essential experience

  • Former healthcare-services CEO, chief medical officer, clinical-network leader, hospital or fertility-platform executive, healthcare investor, operating partner or senior healthcare advisor with enterprise-level responsibility.
  • Experience scaling a multi-site clinical business while maintaining quality, patient safety and professional accountability.
  • Direct involvement in acquisitions, clinical partnerships, greenfield centre launches or integration of founder-led healthcare assets.
  • Ability to interpret clinical outcomes, patient pathways, centre economics, clinician incentives and investment returns together.
  • Experience handling a material clinical-quality concern, clinician conflict, adverse event, patient-trust issue or post-acquisition remediation.
  • Confidence to advise experienced founders, specialist clinicians and private-equity investors without becoming aligned to one constituency.

Strong differentiators

  • Fertility, reproductive medicine, women’s health, embryology, genetics or other laboratory-dependent specialty-care experience.
  • Private-equity portfolio governance, healthcare buy-and-build or operating-partner experience.
  • Clinical-quality, accreditation, patient-safety or medical-ethics leadership.
  • Multi-city healthcare consumer branding and responsible patient acquisition.
  • Healthcare technology, sensitive-data governance or AI-supported clinical workflows.
  • Experience preparing a healthcare company for institutional investment, strategic sale or public-market scrutiny.

Leadership attributes

  • Sound judgement under clinical, commercial and emotional complexity.
  • Respect for clinical independence combined with intolerance for unexamined variation or poor evidence.
  • Ability to challenge investment assumptions without losing sight of execution realities.
  • Strong listening skills and credibility with clinicians, operators, founders and investors.
  • Comfort operating through influence rather than authority.
  • Personal integrity, discretion and willingness to surface difficult concerns early.
  • Clear understanding of the boundary between advice, governance and management.

Role boundaries

The Board Advisor will:

  • Attend agreed Board or strategy sessions as an invited advisor.
  • Submit observations and recommendations to the Chair, Board or management through defined channels.
  • Participate in selected clinical-quality, investment, integration and talent reviews.
  • Undertake agreed clinic and laboratory visits with appropriate confidentiality and patient safeguards.
  • Coach senior leaders where specifically requested and where no conflict is created.

The Board Advisor will not:

  • Serve as a statutory director or exercise a Board vote.
  • Approve investments, acquisitions, budgets, reserved matters or clinical policies.
  • Direct patient care, issue clinical instructions or review identifiable cases beyond an authorised governance process.
  • Represent the company before a regulator, court, investor or counterparty unless separately authorised in writing.
  • Negotiate transactions, introduce acquisition targets for compensation or receive a success fee.
  • Act as an alternative reporting line for executives or bypass the Chief Executive Officer.

Independence and conflicts

The advisor must provide objective counsel to the Board as a whole, even though the appointment is not a statutory independent-director position. The candidate must disclose relationships with the sponsor, founders, co-investors, lenders, acquisition targets, competing healthcare networks, clinicians, referral sources, laboratories, genetic-testing companies, pharmaceutical suppliers, equipment vendors, auditors and professional advisers.

Financial interests, advisory retainers, board roles, speaking fees, research support, clinical practice, patient-referral arrangements, transaction interests and close-relative relationships will be assessed before appointment and monitored throughout the term.

The following are incompatible with the role unless expressly resolved by the Board after full disclosure:

  • Compensation contingent on an acquisition, financing, vendor appointment or future exit.
  • A current operating or advisory role with a direct competitor or active acquisition target.
  • Patient or clinician referral commissions.
  • Financial interests in products, laboratories or vendors whose selection the advisor may influence.
  • Undisclosed sponsor, founder or management relationships that could impair objective advice.
  • Use of confidential clinical, transaction or patient information for another portfolio company or investment activity.

Eligibility

IICA Independent Directors Databank membership is not required for this appointment. The role does not require an IICA proficiency certificate or prior experience as a statutory Independent Director.

Candidates must nevertheless satisfy the company’s background, confidentiality, reputation, conflict and professional-credential checks. Any medical or other professional qualification presented as part of the candidate’s suitability must be current and verifiable where applicable.

Information available before acceptance

The preferred candidate will receive confidential access to the shareholder and governance structure, investment thesis, operating plan, centre portfolio, outcome definitions, clinical-quality dashboards, laboratory architecture, serious incidents, patient complaints, clinician arrangements, marketing channels, unit economics, acquisition pipeline, integration performance, key litigation, data and cyber posture, insurance coverage and the proposed advisory agreement.

The candidate will meet the Chair, sponsor representatives, founders, Chief Executive Officer, clinical leadership, laboratory leadership and selected functional heads. At least one clinic and embryology-laboratory visit will form part of the mutual diligence process.

First 100 days

  • Assess whether the stated clinical and commercial strategy can be delivered by the current network model and leadership capacity.
  • Identify the five highest-consequence clinical, laboratory, patient and acquisition risks requiring Board attention.
  • Review outcome definitions, data provenance and the claims currently made to patients and investors.
  • Examine clinical-leadership authority, embryology succession, incident escalation and speaking-up culture.
  • Test the investment case and integration status of recent acquisitions or planned centre launches.
  • Agree a concise advisory scorecard covering clinical quality, ethical growth, centre economics, integration and leadership.
  • Recommend decision gates for acquisitions, new laboratories, significant treatment offerings and clinical technologies.

Outcomes expected by month 12

  • A Board-endorsed strategic identity and network model with clear choices on services, cities and centre formats.
  • Comparable, risk-adjusted and independently credible clinical outcome reporting across the network.
  • Stronger laboratory governance, chain-of-identity controls, emergency readiness and specialist succession.
  • Ethical standards for patient acquisition, treatment add-ons, outcome claims, consent, counselling and clinician incentives.
  • A repeatable acquisition and integration playbook that treats clinical quality and leadership character as investment conditions.
  • Centre-level economics that connect revenue and cash with patient journey, clinical capacity and quality.
  • Defined governance for reproductive, genetic and family data, including acquired datasets and AI use.
  • A leadership and culture plan that reduces dependence on individual founders, clinicians and embryologists.
  • A value-creation trajectory capable of supporting future institutional diligence without compromising patient trust.

Application

Applications should include a current executive or Board advisory résumé, a complete schedule of healthcare investments and advisory positions, and a concise account of one difficult clinical-growth, healthcare-integration or patient-trust decision personally influenced.

Candidates should also disclose relationships relevant to fertility care, women’s health, laboratories, private equity, healthcare acquisitions and likely commercial counterparties.

Shortlisted candidates will participate in a Board advisory case involving acquisition of a founder-led fertility centre, inconsistent outcome data, clinician-retention pressure and a time-sensitive expansion decision.

Board Portfolio Development & Positioning

A CXO résumé is not a board portfolio.

Nomination & Remuneration Committees assess governance judgment, committee readiness, independence and sector relevance — not your employment history alone. Your experience is senior. Does your profile read like a board appointment?

We translate your executive career into the format NRCs expect — governance contribution, committee relevance, sector credibility and the specific value you bring to a board.

  • Board-ready one-page profile
  • Full Independent Director portfolio
  • Governance, committee & sector positioning
  • Crafted specifically for NRC review

Portfolio Builder — ₹25,000 + GST · included at no additional cost with Foresight

New to Pharma & Healthcare boards?

What these boards look for, how the committees are composed, what the seats pay, and the eligibility rules that apply.

Other board seats aligned to your profile

India ID ExchangeLong Term

Audit Committee Chair — Communications Infrastructure, Customer Trust and Technology Risk

Confidential listed communications-services company Delhi NCR· Communications Infrastructure and Services
Upcoming Foresight Priority PeriodAudit Committee Chair & Financial Expert First-timer eligibilityForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →AuditRiskNRC

The Audit Committee Chair must understand how capital, customer usage, service availability, partner settlements, billing, spectrum or licence obligations, technology assets and cyber risk combine in the financial result. The Board does not need an engineer who approves network design; it needs a…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 41d 17:39:00· 27 December 2026 at 11:59 pm IST
Posted 23 OctApply
India ID ExchangeLong Term

Stakeholders Relationship Committee Chair — Trust, Disclosure and Digital Service Accountability

Confidential listed technology-services company Mumbai· Technology Services
Upcoming Foresight Priority PeriodGeneral Independent Director First-timer eligibilityForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →StakeholdersCSR

The Board seeks a director to chair Stakeholders Relationship and contribute to CSR. The formal duties—shareholder servicing, transfers, dematerialisation, grievances and compliance—remain essential. The opportunity is to turn recurring questions, delayed resolution and communication gaps into…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 38d 17:39:00· 24 December 2026 at 11:59 pm IST
Posted 22 OctApply
India ID ExchangeLong Term

Independent Director — Audit, NRC and Risk in Advanced Industrial Manufacturing

Confidential listed industrial manufacturing company Vadodara· Advanced Industrial Manufacturing
Upcoming Foresight Priority PeriodGeneral Independent DirectorAuditNRCRisk

The appointee will serve on Audit, NRC and Risk without being recruited to dominate any of them. The Board is looking for a director who can bring independent synthesis: listen to specialists, identify the assumption that connects their reports, and ask the question that changes a decision. Strong…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 43d 17:39:00· 29 December 2026 at 11:59 pm IST
Posted 20 OctApply
India ID ExchangeLong Term

Audit Committee Chair and Risk Member — Listed Investment and Financial Services Company

Confidential listed investment and financial services company Mumbai· Investment and Financial Services
Upcoming Foresight Priority PeriodAudit Committee Chair & Financial Expert First-timer eligibilityForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →AuditRisk

The Audit Committee Chair will apply three tests to every material issue. Is the number supported? Is the customer or investor treated fairly? Is the control robust when markets and behaviour change? A favourable answer to only one or two is not sufficient in a business that manages money,…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 34d 17:39:00· 20 December 2026 at 11:59 pm IST
Posted 19 OctApply